echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > 【Focus on the frontier】AI diagnosis of acute promyelocytic leukemia

    【Focus on the frontier】AI diagnosis of acute promyelocytic leukemia

    • Last Update: 2022-10-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Since the introduction of trans-retinoic acid and arsenic trioxide, acute promyelocytic leukemia (APL, identified by the FAB collaborative group as acute myeloid leukemia M3 type, hence the name M3 leukemia) has become the most potential subtype


     

    However, the disease is characterized by a high mortality rate early (10%-17%), mainly due to severe coagulation disorders


     

    Diagnostic points for APL

    1.


    References:

    Cheli E, Chevalier S, Kosmider O, Eveillard M, Chapuis N, Plesa A, Heiblig M, Andre L, Pouget J, Mossuz P, Theisen O, Alcazer V, Gugenheim D, Autexier N, Sujobert P.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.